Myasthenia gravis (MG) in children and adolescents to age 18 -- juvenile MG -- includes clinically significant developmental ...

The U.S. Intravenous Immunoglobulin Market plays a crucial role in treating immunodeficiency diseases and various autoimmune disorders, reflecting a steady evolution influenced by advanced therapies ...

HOUSE, PA — Johnson & Johnson (NYSE: JNJ) has unveiled new data demonstrating the efficacy of IMAAVY™ (nipocalimab-aahu) for the treatment of generalized myasthenia gravis (gMG). Presented at the ...

In this interview, Richard J. Nowak, MD, MS, principal investigator of the MINT trial of inebilizumab for generalized myasthenia gravis (gMG), discusses the trial’s key findings, including significant ...

Telitacicept is a dual-targeting agent that attaches to and blocks the effects of 2 key signaling proteins, B-lymphocyte ...